Provided by Tiger Fintech (Singapore) Pte. Ltd.

Taysha Gene Therapies, Inc.

2.85
+0.00500.18%
Volume:1.13M
Turnover:3.17M
Market Cap:745.39M
PE:-8.51
High:2.93
Open:2.90
Low:2.77
Close:2.84
Loading ...

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for Tsha-102 in Rett Syndrome Enabled by Irsf Natural History Data and Positive Clinical Data From Part a of the Reveal Adult/Adolescent and Pediatric Trials Evaluating Tsha-102

THOMSON REUTERS
·
29 May

Truist Financial Sticks to Its Buy Rating for Taysha Gene Therapies (TSHA)

TIPRANKS
·
16 May

Stock Track | Taysha Gene Therapies (TSHA) Soars 5.47% on Positive Analyst Ratings

Stock Track
·
16 May

Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
16 May

Taysha Gene Therapies (TSHA) Gets a Buy from Citizens JMP

TIPRANKS
·
16 May

Taysha Gene Therapies’ Positive Q1 2025 Earnings Call

TIPRANKS
·
16 May

Taysha Gene Therapies Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Taysha Gene Therapies Q1 EPS $(0.08) Beats $(0.09) Estimate, Sales $2.30M Beat $1.71M Estimate

Benzinga
·
15 May

BRIEF-Taysha Gene Therapies Q1 Net Income USD -21.529 Million Vs. IBES Estimate USD -22.6 Million

Reuters
·
15 May

Taysha Gene Therapies Q1 Basic EPS USD -0.08

THOMSON REUTERS
·
15 May

Taysha Gene Therapies Q1 EPS USD -0.08 VS. Ibes Estimate USD -0.09

THOMSON REUTERS
·
15 May

Taysha Gene Therapies Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
13 May

Taysha Gene Therapies Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
10 May

BUZZ-Gene therapy and vaccine makers fall after FDA names Vinay Prasad as top vaccine official

Reuters
·
07 May

U.S.-Listed Shares of CRISPR Therapeutics Fall 10.3%, Sarepta Therapeutics Fall 20.2%

THOMSON REUTERS
·
07 May

Gene Therapy Makers Fall After US FDA Names Oncologist Vinay Prasad as Top Vaccine Official

THOMSON REUTERS
·
07 May

BRIEF-Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
02 May

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May

Taysha Gene Therapies assumed with an Overweight at Piper Sandler

TIPRANKS
·
01 May

Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald

Dow Jones
·
28 Apr